Sam Altman once suggested that one day, AI would provide answers about making money, a notion that resonates with Max Hodak, co-founder and CEO of Science Corp. Hodak, who previously led Neuralink, now aims to push boundaries in brain-computer interface (BCI) technology. He emphasizes that while neuroscience itself isn’t groundbreaking, the engineering advancements—like creating smaller, safer implants—are significant. His company has raised $260 million to develop practical solutions, including affordable tools for researchers. Science Corp.'s first commercial product, Prima, is a chip implanted in the retina that can restore vision in patients with advanced macular degeneration. In clinical trials, 80% of participants regained the ability to read. The product, refined from technology acquired from Pixium Vision, is set for a European launch next summer, with a U.S. release pending FDA approval. Each procedure is expected to cost around $200,000, with profitability achievable by treating just 50 patients monthly. Looking ahead, Hodak aims to innovate with optogenetic gene therapy, which would make neurons responsive to light, eliminating the need for electrodes. While other companies are pursuing similar approaches, Hodak believes his method is superior in speed and sensitivity. The ultimate goal involves growing new brain tissue, a concept Science Corp. has tested in mice with a prototype device. This work could revolutionize treatments for spinal cord injuries and blindness by expanding the capabilities of neural interfaces.